Industry data shows small molecules achieve 5–10% approval rates over 15–20 years; antisense oligonucleotides (“ASOs”) are shifting the odds through rational design. Six new antisense drugs gained FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback